Avidity Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical firm specializing in RNA therapeutics, will participate in two upcoming conferences. The Credit Suisse 30th Annual Healthcare Conference is scheduled for November 10, 2021, at 2:40 PM ET. Following that, the 4th Annual Evercore ISI HealthCONx Conference will take place on November 30, 2021, at 10:05 AM ET. Live webcasts and archived replays of both events will be available on the company’s website.

LA JOLLA, Calif., Nov. 2, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following conferences:

Credit Suisse 30th Annual Healthcare Conference
November 10^th, 2021
Fireside Chat @ 2:40pm ET

4th Annual Evercore ISI HealthCONx Conference
November 30^th, 2021
Fireside Chat @ 10:05am ET

Live webcasts of each event, as well as an archived replay of the webcasts following each event, will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity

Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs^TM). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1). The FDA has cleared Avidity to proceed with the Phase 1/2 MARINA^TM trial of AOC 1001 in adults with DM1. Its advancing and expanding pipeline also includes programs in facioscapulohumeral muscular dystrophy (FSHD), Duchenne Muscular Dystrophy (DMD), muscle atrophy and Pompe disease. The company is planning for AOC 1044, the lead of three programs for the treatment of DMD, and its AOC FSHD program to enter the clinic in 2022.  Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in La Jolla, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.

Company Contact:
Kath Gallagher
kath.gallagher@aviditybio.com
(858) 401-7900

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301413250.html

SOURCE Avidity Biosciences, Inc.

FAQ

When will Avidity Biosciences participate in the Credit Suisse Conference?

Avidity Biosciences will participate in the Credit Suisse 30th Annual Healthcare Conference on November 10, 2021, at 2:40 PM ET.

What is the date of Avidity Biosciences' participation in the Evercore ISI Conference?

Avidity Biosciences will participate in the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 10:05 AM ET.

Where can I watch the webcasts of Avidity Biosciences' conferences?

The live webcasts and archived replays of Avidity Biosciences' conference presentations will be available on the 'Events and Presentations' page of their website.

What is Avidity Biosciences' main focus in biotechnology?

Avidity Biosciences focuses on RNA therapeutics, particularly Antibody Oligonucleotide Conjugates (AOCs™), targeting diseases previously considered untreatable.

What is the ticker symbol for Avidity Biosciences?

The ticker symbol for Avidity Biosciences is RNA.